BRSYF Quote, Financials, Valuation and Earnings

Compugen Ltd. has a net margin of 11.59% compared to Brainsway Ltd.'s net margin of 84.43%. Brainsway Ltd.'s return on equity of 10.13% beat Compugen Ltd.'s return on equity of 57.22%.

Brainsway Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Compugen Ltd. has an analysts' consensus of $5.80 which suggests that it could grow by 190%. Given that Compugen Ltd. has higher upside potential than Brainsway Ltd., analysts believe Compugen Ltd. is more attractive than Brainsway Ltd..

Brainsway Ltd. has a beta of 20.276, which suggesting that the stock is 1927.646% more volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.896, suggesting its more volatile than the S&P 500 by 189.647%.

Brainsway Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Brainsway Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.

Brainsway Ltd. quarterly revenues are $13.5M, which are smaller than Compugen Ltd. quarterly revenues of $67.3M. Brainsway Ltd.'s net income of $1.6M is lower than Compugen Ltd.'s net income of $56.8M. Notably, Brainsway Ltd.'s price-to-earnings ratio is 76.14x while Compugen Ltd.'s PE ratio is 55.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Brainsway Ltd. is 9.14x versus 2.57x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Pluri, Inc. has a net margin of 11.59% compared to Brainsway Ltd.'s net margin of -3470.71%. Brainsway Ltd.'s return on equity of 10.13% beat Pluri, Inc.'s return on equity of -5662.45%.

Brainsway Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Pluri, Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 239.93%. Given that Pluri, Inc. has higher upside potential than Brainsway Ltd., analysts believe Pluri, Inc. is more attractive than Brainsway Ltd..

Brainsway Ltd. has a beta of 20.276, which suggesting that the stock is 1927.646% more volatile than S&P 500. In comparison Pluri, Inc. has a beta of 0.663, suggesting its less volatile than the S&P 500 by 33.7%.

Brainsway Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Brainsway Ltd. pays -- of its earnings as a dividend. Pluri, Inc. pays out -- of its earnings as a dividend.

Brainsway Ltd. quarterly revenues are $13.5M, which are larger than Pluri, Inc. quarterly revenues of $198K. Brainsway Ltd.'s net income of $1.6M is higher than Pluri, Inc.'s net income of -$6.9M. Notably, Brainsway Ltd.'s price-to-earnings ratio is 76.14x while Pluri, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Brainsway Ltd. is 9.14x versus 21.56x for Pluri, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

XTL Biopharmaceuticals Ltd. has a net margin of 11.59% compared to Brainsway Ltd.'s net margin of -341.36%. Brainsway Ltd.'s return on equity of 10.13% beat XTL Biopharmaceuticals Ltd.'s return on equity of -34.34%.

Brainsway Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand XTL Biopharmaceuticals Ltd. has an analysts' consensus of -- which suggests that it could grow by 3770.97%. Given that XTL Biopharmaceuticals Ltd. has higher upside potential than Brainsway Ltd., analysts believe XTL Biopharmaceuticals Ltd. is more attractive than Brainsway Ltd..

Brainsway Ltd. has a beta of 20.276, which suggesting that the stock is 1927.646% more volatile than S&P 500. In comparison XTL Biopharmaceuticals Ltd. has a beta of 1.193, suggesting its more volatile than the S&P 500 by 19.26%.

Brainsway Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XTL Biopharmaceuticals Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Brainsway Ltd. pays -- of its earnings as a dividend. XTL Biopharmaceuticals Ltd. pays out -- of its earnings as a dividend.

Brainsway Ltd. quarterly revenues are $13.5M, which are larger than XTL Biopharmaceuticals Ltd. quarterly revenues of $162K. Brainsway Ltd.'s net income of $1.6M is higher than XTL Biopharmaceuticals Ltd.'s net income of -$553K. Notably, Brainsway Ltd.'s price-to-earnings ratio is 76.14x while XTL Biopharmaceuticals Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Brainsway Ltd. is 9.14x versus 13.79x for XTL Biopharmaceuticals Ltd.. Usually stocks with elevated PS ratios are considered overvalued.